175 related articles for article (PubMed ID: 18653595)
1. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results.
Arias L; Planas N; Prades S; Caminal JM; Rubio M; Pujol O; Roca G
Br J Ophthalmol; 2008 Aug; 92(8):1035-9. PubMed ID: 18653595
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.
Yamamoto I; Rogers AH; Reichel E; Yates PA; Duker JS
Br J Ophthalmol; 2007 Feb; 91(2):157-60. PubMed ID: 16870653
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results.
Gharbiya M; Allievi F; Mazzeo L; Gabrieli CB
Am J Ophthalmol; 2009 Jan; 147(1):84-93.e1. PubMed ID: 18774547
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up.
Lorenzo D; Arias L; Alcubierre R; Pujol O; Caminal JM; Rubio M; Català J; Garcia-Bru P; Arruga J
Ophthalmologica; 2011; 226(3):103-9. PubMed ID: 21720153
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.
Sakaguchi H; Ikuno Y; Gomi F; Kamei M; Sawa M; Tsujikawa M; Oshima Y; Kusaka S; Tano Y
Br J Ophthalmol; 2007 Feb; 91(2):161-5. PubMed ID: 16914470
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia.
Parodi MB; Iacono P; Papayannis A; Kontadakis S; Cascavilla ML; Zucchiatti I; Bandello F
Retina; 2013 Mar; 33(3):593-7. PubMed ID: 23190919
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome.
Ruiz-Moreno JM; Montero JA; Gomez-Ulla F; Ares S
Br J Ophthalmol; 2009 Apr; 93(4):448-51. PubMed ID: 19091851
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
12. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia.
Hernández-Rojas ML; Quiroz-Mercado H; Dalma-Weiszhausz J; Fromow-Guerra J; Amaya-Espinosa A; Solís-Vivanco A; Reyna-Castelán E; Abraham-Marín M; Martínez-Castellanos MA; Aiello LP
Retina; 2007; 27(6):707-12. PubMed ID: 17621179
[TBL] [Abstract][Full Text] [Related]
13. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial.
Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB
Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study.
Chan WM; Lai TY; Liu DT; Lam DS
Br J Ophthalmol; 2009 Feb; 93(2):150-4. PubMed ID: 18801766
[TBL] [Abstract][Full Text] [Related]
15. Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization.
Sabry D; Gad MA; Enam KM
Retina; 2013 Mar; 33(3):598-605. PubMed ID: 23064427
[TBL] [Abstract][Full Text] [Related]
16. Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization.
Ruiz-Moreno JM; Montero JA; Arias L; Araiz J; Gomez-Ulla F; Silva R; Piñero DP
Retina; 2010; 30(10):1609-15. PubMed ID: 20856171
[TBL] [Abstract][Full Text] [Related]
17. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results.
Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Ares S; Lopez-Lopez F; Rodriguez M; Fernandez M
Eye (Lond); 2009 Feb; 23(2):334-8. PubMed ID: 18064056
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
Ikuno Y; Sayanagi K; Soga K; Sawa M; Tsujikawa M; Gomi F; Tano Y
Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of intravitreal bevacizumab injection for choroidal neovascularization secondary to angioid streaks.
Sawa M; Gomi F; Tsujikawa M; Sakaguchi H; Tano Y
Am J Ophthalmol; 2009 Oct; 148(4):584-590.e2. PubMed ID: 19541288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
